We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pulls Multiple Myeloma Drug Pepaxto From Market After Failing Phase 3 Study
FDA Pulls Multiple Myeloma Drug Pepaxto From Market After Failing Phase 3 Study
The FDA is withdrawing its approval of Oncopeptides’ multiple myeloma drug Pepaxto (melphalan flufenamide), effectively ending a three-year tug-of-war over the controversial drug’s future.